Continuing Education Activity

Postpartum thyroiditis (PPT) is a destructive autoimmune thyroiditis that presents within 1 year after delivery and most often follows a biphasic course consisting of transient thyrotoxicosis followed by hypothyroidism. The condition is associated with thyroid peroxidase antibodies, sometimes thyroglobulin antibodies, and genetic susceptibility and frequently overlaps symptomatically with typical postpartum changes. Laboratory findings during the thyrotoxic phase include high or high-normal free T4 and free T3 levels, accompanied by a suppressed thyroid-stimulating hormone (TSH). In contrast, the hypothyroid phase is characterized by low levels of free thyroxine (T4), with a subsequent rise in TSH after pituitary recovery. Differentiation from Graves disease relies on clinical context, a high triiodothyronine-to-thyroxine (T3:T4) ratio, positive TSH-receptor antibodies in Graves disease, and low radioiodine uptake in PPT. Most cases remit within 12 months, although permanent hypothyroidism develops in a minority, with recurrence common in subsequent pregnancies. High-risk cohorts include individuals with type 1 diabetes, prior PPT, or positive thyroid autoantibodies. Early recognition, appropriate testing, and structured follow-up reduce missed transitions and long-term complications.

Participants of this course learn to recognize PPT early, interpret thyroid function patterns across phases, and distinguish PPT from Graves disease using TSH-receptor antibody testing and, when needed, radioiodine uptake. Management principles emphasize symptom control with beta-blockers during thyrotoxicosis, selective levothyroxine for clinically significant hypothyroidism, medication safety during lactation, and scheduled reassessment of TSH and free T4. Collaboration with an interprofessional team enhances outcomes: the clinician synthesizes diagnostics and determines the timing of treatment; nurses standardize education, return precautions, and mood-disorder screening; pharmacists optimize drug choice and dosing during lactation; and behavioral-health professionals address coexisting postpartum depression or anxiety. Shared decision-making, clear role delineation, and coordinated follow-up improve endocrine stability, sustain breastfeeding goals, and support maternal–infant well-being.

Objectives:

• Determine optimal timing for initiating treatment, including beta-blockers for thyrotoxicosis or selective levothyroxine for hypothyroidism.
• Differentiate postpartum thyroiditis from Graves disease using appropriate diagnostic testing.
• Assess clinical signs and symptoms of thyrotoxicosis and hypothyroidism, including subtle manifestations overlapping with normal postpartum changes.
• Improve interprofessional communication by coordinating clinicians, nurses, pharmacists, and behavioral health specialists to align testing, lactation counseling, medication safety, and mental health screening.

Introduction

The thyroid gland is a butterfly-shaped endocrine organ located in the anterior neck that produces thyroid hormones, including thyroxine (T4) and triiodothyronine (T3), which regulate metabolism, energy homeostasis, and mood. Postpartum thyroiditis (PPT) is a destructive autoimmune inflammatory condition of the thyroid gland that occurs within 1 year after delivery in individuals who were previously euthyroid and without Graves disease or toxic nodules.[1] Postpartum thyroiditis has also occurred after spontaneous or induced abortions.[2] Lymphocytic infiltration and inflammation of the thyroid gland result in a transient disruption of hormone production and release. PPT affects approximately 5% to 10% of individuals in the postpartum period. However, the incidence may be higher in those with pre-existing autoimmune disorders such as type 1 diabetes or a personal or family history of thyroid disease. Because its symptoms often overlap with typical postpartum changes, such as fatigue, mood swings, and weight fluctuations, PPT is often underrecognized and misattributed to other causes.[3]

Postpartum thyroiditis can be either a transient or permanent thyroid disease, typically following a biphasic pattern. The initial phase is thyrotoxic, occurring between 1 and 4 months postpartum, as stored hormones are released from the inflamed gland. This phase may be asymptomatic or present with palpitations, anxiety, heat intolerance, or fatigue. The thyrotoxic phase is followed by a hypothyroid phase, usually around 4 to 8 months postpartum, characterized by low energy, cold intolerance, weight gain, and depression. Many cases resolve spontaneously within 12 months, though some individuals may develop permanent hypothyroidism.[4] The effects of PPT can impact cardiovascular, neurological, and metabolic function. Additionally, unrecognized or poorly managed cases can contribute to long-term thyroid dysfunction, underscoring the need for early diagnosis and coordinated interprofessional care.   

Etiology

PPT is an autoimmune disease associated with thyroid peroxidase (TPO) antibodies.[5] PPT is a destructive thyroiditis characterized by lymphocytic infiltration of the thyroid gland. Histopathologic features of PPT are similar to those of Hashimoto thyroiditis. Postpartum thyroiditis is associated with certain human leukocyte antigen (HLA) haplotypes, particularly HLA-DR3, HLA-DR4, and HLA-DR5 from the class II region, and HLA-B8 and HLA-Bw35 from the class I region. These genetic markers are linked to autoimmune thyroid disease and may predispose to thyroid autoimmunity.[6] Their presence may also indicate a higher risk of developing permanent hypothyroidism after the postpartum period, underscoring the role of inherited risk factors.[7][8]

TPO antibodies are common in autoimmune thyroid disorders, including Graves disease and Hashimoto thyroiditis. Furthermore, the titer of TPO antibodies correlates with the degree of lymphocytic infiltration in the thyroid gland. These antibodies activate the complement system, triggering antibody-dependent, cell-mediated cytotoxicity.[9]

Epidemiology

PPT affects approximately 1 in 20 postpartum individuals (5% to 8%).[3][10] The prevalence of an abnormal thyroid-stimulating hormone (TSH) level during the postpartum period is approximately 8% worldwide and up to 19.6% in patients with type 1 diabetes.[1] Reported prevalence varies across cohorts, ranging from approximately 1% to 16% of pregnancies; many reviews cite a prevalence of around 8%. Multiple factors influence the rates, including the duration of follow-up in the postpartum period and the iodine status of the studied populations. For example, in Thailand, the reported incidence is 1.1%, whereas the incidence in Brazil is 13.3%. People in both regions have low iodine intake. Prevalence of PPT in high-risk individuals, including those with type 1 diabetes mellitus and a family history of postpartum thyroiditis, is estimated to be between 19.1% and 20.0%, respectively. Notably, the recurrence risk in a patient with a history of PPT is greater than 42%.[11][12] PPT is also more common in patients with thyroid peroxidase (TPOAb) and thyroglobulin (TgAb) antibodies.[2]

Individuals at high risk should be closely monitored and evaluated regularly. High-risk patients include those with a prior history of PPT, who have a 50% to 70% chance of recurrence, and those with preexisting Hashimoto thyroiditis requiring thyroid hormone therapy, who have a similar risk of 50% to 68%. Risk factors for PPT include type 1 diabetes (22.5%), chronic hepatitis (25%), the presence of thyroid peroxidase antibodies (25%), and a personal history of other autoimmune diseases not involving the thyroid, which may have a risk ranging from 4% to 26%.[3] Interestingly, individuals with chronic hepatitis, particularly those with hepatitis C or autoimmune hepatitis, often have TPO antibodies despite the absence of overt thyroid disease.

Pathophysiology

During pregnancy, TPOAb levels naturally decrease due to the relative immunosuppression that occurs during pregnancy. In the postpartum period, cellular and humoral immunity reconstitution may lead to PPT. Immune reconstitution after childbirth occurs in 2 phases: Cellular immunity begins to reactivate between 1 and 4 months postpartum, followed by a rise in humoral immunity at 7 to 10 months. The initial reactivation of cellular immunity is associated with worsening or onset of Graves disease, Hashimoto thyroiditis, and PPT.[1] 

The inflammatory process in PPT is initiated by thyroid antibodies (TPOAb and TgAb), complement activation, increased levels of IgG1, lymphocyte abnormalities, increased activity of natural killer cells, and specific HLA haplotypes. The inflammatory process activates the proteolysis of thyroglobulin within the thyroid follicles. The destruction and inflammation of the thyroid follicles lead to the unregulated release of thyroid hormone from these damaged cells.[2] Significant amounts of thyroxine (T4) and triiodothyronine (T3) are released into the blood, and a hyperthyroid state results. This hyperthyroid state is transient and lasts until all thyroglobulin stores are released into circulation and depleted. During this hyperthyroid state, the synthesis of new hormones ceases because excessive T4 and T3 in circulation cause downregulation of TSH secretion. Synthesis of thyroid hormones resumes once the inflammatory process subsides.

Three clinical presentations are described for PPT: (1) transient hyperthyroidism (30%), (2) transient hypothyroidism (approximately 43%), and (3) transient hyperthyroidism followed by hypothyroidism and then recovery, which is the classic form of PPT (25%). Classic PPT follows a biphasic pattern. The brief hyperthyroid phase typically begins within the first 6 months after delivery and lasts a few months, followed by a hypothyroid phase that can last up to a year. Most individuals eventually return to euthyroidism within 3 to 6 months, but 20% to 50% may develop permanent hypothyroidism. The most common clinical presentation is hypothyroidism, likely because the earlier hyperthyroid phase often goes unrecognized.[3]

Histopathology

The thyroid gland is composed of follicles, containing colloid, surrounded by follicular cells. The pathophysiology of PPT is characterized by immunomediated cytolysis.[13] Histopathologic findings include prominent lymphocytic infiltration, including associated germinal centers, and the collapse of thyroid follicles. Fine-needle aspiration of the thyroid gland demonstrates follicular cells, lymphocytes, and an accumulation of colloid. During the recovery phase, follicles return to normal, but some degree of fibrosis and lymphocytic infiltration persists.

History and Physical

Most patients with PPT have symptoms that are easily misattributed to routine postpartum symptoms from hormonal changes, sleep deprivation, and caring for a newborn.[1] Additionally, symptoms may not begin until after the 6-week postpartum visit, prompting the patient to seek care outside of the usual schedule.[3] The thyrotoxic state often demonstrates mild symptoms, including irritability, palpitations, fatigue, and heat intolerance. The hypothyroid phase may be symptomatic, with constipation, dry skin, fatigue, impaired concentration, cold intolerance, and paresthesia. Moreover, patients with PPT and TPO antibodies may be more symptomatic than those without.[14]

Evaluation

The diagnosis of PPT is based on clinical presentation and thyroid function tests (levels of TSH and free T4). Patients with postpartum thyroiditis exhibit similar biochemical findings to those with painless thyroiditis, characterized by high or upper limit of normal serum free T4 and T3 levels, and a suppressed TSH level in the hyperthyroid phase, which can be subclinical or overt. In patients with a hyperthyroid state followed by a hypothyroid state, serum T4 levels may be low for days to weeks before serum TSH levels rise above the reference range due to the prolonged suppression of TSH that occurs in the hyperthyroid state. Serum levels of thyroid peroxidase antibody are high in 60% to 85% of patients with postpartum thyroiditis and are highest in the hypothyroid state or soon thereafter. Some patients may have a slight increase in C-reactive protein or erythrocyte sedimentation rate testing.[15][16][17]

Occasionally, PPT does not exhibit any unique physical signs or symptoms. The thyroid is typically nontender. However, a physical examination can help evaluate the severity of hyperthyroidism. In more severe cases, signs may include irregular heart rhythms such as atrial fibrillation, signs of right-sided heart failure, elevated body temperature, and changes in mental status.[3] 

Patients at high risk for PPT or with symptoms of hyperthyroidism, hypothyroidism, postpartum depression, or lactation difficulties should have their TSH checked during the 6-12 weeks postpartum.[1][3] Hyperthyroidism may interfere with the normal release of oxytocin, leading to the accumulation of milk within the breast, which can trigger apoptosis in the milk-producing glands and negatively impact lactation.[18] In a case-control study involving 178 women, lactation difficulties were reported by 30% of patients with thyroid dysfunction, compared to 16% of those without. Notably, issues with milk production often appear before other signs of thyroid dysfunction.[1][3]

Screening of high-risk individuals for PPT, such as those with TPO antibodies, a history of postpartum thyroiditis, and type 1 diabetes mellitus, is recommended by the Endocrine Society clinical practice guidelines. High-risk patients should have their serum TSH levels evaluated at 3 and 6 months postpartum.[19] However, TSH within the reference range at 6 weeks postpartum may not exclude PPT, as the sensitivity is 53% and the specificity is 100% during this period. In postpartum thyroiditis, symptoms often appear before any biochemical changes are detected. Postpartum individuals experiencing symptoms with a normal TSH result may be in the transitional period between the thyrotoxic and hypothyroid phases. Repeat TSH testing in 4 to 6 weeks is warranted in high-risk patients to monitor for any changes.[1][3]

The first step in evaluating thyroid dysfunction is measuring TSH levels. Suppose TSH level results are abnormal, either elevated or decreased. In that case, free T4 levels can help determine whether the patient has subclinical thyroid disease (normal free T4 with abnormal TSH results) or overt disease (both TSH and free T4 results are abnormal). When TSH levels are low, measuring free T3 levels may be helpful; a high T4:T3 ratio can support a diagnosis of PPT rather than Graves disease.[3]

The hyperthyroid phase of PPT is diagnosed when TSH levels are low, free T4 and free T3 levels are elevated, and thyroid-stimulating immunoglobulin (TRAb) results are negative. Antibody testing for TRAb is a highly specific and sensitive marker for Graves disease.[10][20][21] TRAb targets the TSH receptor on the thyroid gland and stimulates it, leading to the overproduction of thyroid hormones, a hallmark of Graves disease. To further differentiate PPT from Graves disease, a radioactive iodine uptake scan may be used. According to the American Thyroid Association, individuals can safely express and discard breast milk after the scan to reduce any risk to the infant. However, some may choose to avoid the test due to concerns about radiation exposure to the infant.[3][22] Notably, radioactive iodine (I-131), used for treating hyperthyroidism, is contraindicated during lactation. Conversely, iodine-123, a diagnostic agent used in thyroid scans, is safer and requires a temporary interruption of breastfeeding for approximately 2 to 3 days.[23] 

Symptoms during the hypothyroid phase of PPT may include difficulty concentrating, forgetfulness, depression, and a general increase in physical or emotional concerns. Thyroid testing is considered appropriate for postpartum individuals experiencing multiple signs of hypothyroidism within the first year after giving birth. The American Thyroid Association, the Endocrine Society, and the American College of Obstetricians and Gynecologists recommend evaluating thyroid function in all postpartum individuals diagnosed with postpartum depression.[3][20] However, results from a more recent study in the Netherlands, which included a prospective population-based cohort study, systematic review, and meta-analysis, did not demonstrate a significant association between postpartum depression and TPO antibodies, TSH, or free T4. This finding may reflect variations in the definition and gestational age at which testing for TPOAb was performed.[20] Because thyroid peroxidase antibodies are present in 6% to 11% of euthyroid women, further studies on this topic are needed to clarify the association.[24]

Treatment / Management

Prospective study results from 605 asymptomatic pregnant and postpartum individuals showed that none of the cases with thyrotoxicosis and 40% of cases with hypothyroid state required treatment. If treatment was necessary, it was typically tapered over a period of 1 year. Long-term treatment is necessary in up to 20% of PPT cases. Because the thyrotoxic state is transitory, it does not require treatment with antithyroid medications. In addition, antithyroid medications (methimazole and propylthiouracil) are ineffective in the treatment of the thyrotoxic state because hormone synthesis is not increased in destructive thyroiditis. When the thyrotoxic state of postpartum thyroiditis resolves, the serum TSH level should be measured after 4 to 8 weeks (or sooner if new symptoms develop) to screen for a hypothyroid state. If symptoms are bothersome, beta-blockers like propranolol (20 mg every 6 hours) can be used, which is generally compatible with breastfeeding; transfer into milk is minimal. Because propranolol is not secreted in breast milk, it is the recommended treatment.[13] 

Guidelines from the Endocrine Society, the American Thyroid Association, and the American College of Obstetricians and Gynecologists agree that thioamides are ineffective for treating the thyrotoxic phase of PPT; however, beta-blockers may help manage symptoms. The American Thyroid Association recommends checking TSH levels 4 to 8 weeks after the thyrotoxic phase to monitor for hypothyroidism, which typically develops between 4 and 8 months after delivery. If TSH levels are between 4 and 10 mIU/L and the patient is asymptomatic, the Endocrine Society suggests retesting in 4 to 8 weeks before starting therapy.[20] Treatment is recommended when the TSH level exceeds 10 mU/L. Individuals who are asymptomatic with an elevated TSH at a level below 10 mIU/L may be monitored if a subsequent pregnancy is not planned. Clinical and laboratory assessments are recommended in 4 to 8 weeks in these cases.[3][20] 

Treatment with levothyroxine (LT4) should be considered in the hypothyroid state of PPT if the patient has significant symptoms, is lactating, or wants to get pregnant again quickly. If treatment is delayed, thyroid function must be evaluated every 4 to 8 weeks until the patient becomes euthyroid. In addition, women must be counseled to use contraception. The optimal duration of LT4 therapy has not been evaluated. Guidelines recommend maintaining euthyroidism during pregnancy and when pregnancy is planned. To assess whether the hypothyroid state of PPT is permanent or transient, LT4 doses can be tapered beginning 12 months after delivery. The dose should be tapered gradually, and serum TSH level should be monitored every 6 to 8 weeks.[14]

Differential Diagnosis

Graves disease is the most important condition to distinguish from PPT. In PPT, the thyrotoxicosis resolves, but in Graves disease, it persists.

Differential diagnosis of postpartum thyroiditis:

• Graves disease

• Hashimoto thyroiditis 

• Postpartum mood disorder[3]

Both PPT and Graves hyperthyroidism can cause elevated TPOAb levels. However, in Graves' disease, the T3:T4 ratio is typically higher (>20:1) due to the increased T3 production. Graves' disease typically appears 6 to 12 months postpartum, whereas PPT usually presents 1 to 4 months after delivery. As noted above, to distinguish between the two, an iodine-123 radioactive uptake scan can be helpful, as iodine uptake is low in PPT and elevated in Graves disease. However, measuring TSH receptor antibodies (TRAb) is often sufficient for differentiating between the 2 conditions.[10]

Prognosis

The prognosis for PPT is generally favorable, as many individuals experience a complete return to euthyroidism within 12 months. Notably, 20% to 50% of cases of PPT will remain in a hypothyroid state 1 year postpartum.[25] Up to 20% of patients, particularly those with TPO antibodies or a history of autoimmune thyroid disease, may develop permanent hypothyroidism requiring lifelong treatment. TSH should be checked annually in these individuals.[20] 

Identifying ongoing hypothyroidism in women preparing for another pregnancy is crucial because untreated or late-treated hypothyroidism in early pregnancy is linked to serious fetal complications, including low birth weight, developmental delays, and neonatal death.[3] Additionally, PPT will recur in approximately 70% of pregnancies.[1][10] These individuals should be monitored closely. With appropriate follow-up and treatment, most patients maintain good long-term health outcomes.

Complications

Complications of PPT include progression to permanent hypothyroidism in up to 20% of affected individuals, especially those with underlying autoimmune disease. Untreated hypothyroidism can lead to fatigue, depression, impaired lactation, and poor maternal-infant bonding. Rarely, severe thyrotoxicosis may contribute to cardiac complications such as palpitations or arrhythmias. Additionally, misdiagnosis or delayed recognition may result in unnecessary treatment or missed postpartum mood disorders.

Deterrence and Patient Education

Deterrence and patient education for PPT focus on awareness, early recognition, and appropriate follow-up. Patients should be informed that PPT is a common, often temporary condition that may cause symptoms mimicking anxiety, depression, or fatigue, and that it can occur even in the absence of prior thyroid disease. Educating high-risk individuals, such as those with type 1 diabetes or positive TPOAb levels, about the potential for PPT enables earlier testing and intervention. Reassurance about the typically self-limited course is essential, along with guidance on when to seek medical attention, particularly if symptoms worsen or persist beyond a few months. Clear communication about the need for periodic thyroid function monitoring helps detect transition to hypothyroidism and prevent long-term complications.

Pearls and Other Issues

PPT often follows a biphasic course of thyrotoxicosis followed by hypothyroidism, and may be mistaken for typical postpartum symptoms or mood disorders. Most cases resolve spontaneously, but up to 20% progress to permanent hypothyroidism. Outpatient monitoring is appropriate, with treatment reserved for symptomatic patients. Beta-blockers may help control symptoms during the thyrotoxic phase, while levothyroxine is used for significant hypothyroidism. A key pitfall is unnecessary treatment with antithyroid drugs (thioamides), which are ineffective in PPT. Patients with type 1 diabetes or positive TPOAb are at higher risk and warrant closer follow-up.

Enhancing Healthcare Team Outcomes

Effective management of postpartum thyroiditis (PPT) requires coordinated, interprofessional collaboration to ensure timely diagnosis, patient safety, and optimal outcomes. Clinicians must use clinical judgment and evidence-based strategies to distinguish PPT from other thyroid disorders and to determine when treatment is necessary, often relying on careful monitoring rather than immediate intervention. Nurses play a critical role in patient education, symptom assessment, and care continuity, ensuring new parents understand the fluctuating nature of PPT and when to seek further evaluation.

Pharmacists contribute by reviewing medication safety for breastfeeding individuals, particularly when beta-blockers or thyroid hormone replacement are needed. Ethical responsibilities include respecting patient autonomy and avoiding overtreatment, especially during the self-limited thyrotoxic phase. Interprofessional communication is essential for coordinating follow-up, especially as PPT can transition into permanent hypothyroidism. Through shared decision-making and role clarity, the healthcare team can enhance patient-centered care, promote safety, and improve long-term outcomes for patients regarding endocrine and mental health.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Peng CC, Pearce EN. An update on thyroid disorders in the postpartum period. J Endocrinol Invest. 2022 Aug;45(8):1497-1506. [PubMed: 35181848]

2.

Świątkowska-Stodulska R, Berlińska A, Stefańska K, Zieliński M, Kwiatkowski S, Połom J, Andrysiak-Mamos E, Wydra P, Sworczak K. Endocrine Autoimmunity in Pregnancy. Front Immunol. 2022;13:907561. [PMC free article: PMC9277138] [PubMed: 35844617]

3.

Epp R, Malcolm J, Jolin-Dahel K, Clermont M, Keely E. Postpartum thyroiditis. BMJ. 2021 Mar 03;372:n495. [PubMed: 33658175]

4.

Benvenga S. Targeted Antenatal Screening for Predicting Postpartum Thyroiditis and Its Evolution Into Permanent Hypothyroidism. Front Endocrinol (Lausanne). 2020;11:220. [PMC free article: PMC7180182] [PubMed: 32362873]

5.

Mladenovic V, Shah R, Medenica S, Dutta P, Zankovic N, Aksam S, Ghosh J, Hussain M, Gluvic Z. Thyroid Gland and Pregnancy - Clinical Update. Horm Metab Res. 2025 May;57(5):303-314. [PubMed: 40460853]

6.

Buczyńska A, Sidorkiewicz I, Hryniewicka J, Zbucka-Krętowska M, Dzięcioł J, Szelachowska M, Krętowski AJ. Pregnancy-associated thyroid disorders: the role of genetic, epigenetic, and oxidative stress factors. Rev Endocr Metab Disord. 2025 Aug;26(4):679-692. [PMC free article: PMC12316717] [PubMed: 40484893]

7.

LiVolsi VA. Postpartum thyroiditis. The pathology slowly unravels. Am J Clin Pathol. 1993 Sep;100(3):193-5. [PubMed: 8379524]

8.

Kologlu M, Fung H, Darke C, Richards CJ, Hall R, McGregor AM. Postpartum thyroid dysfunction and HLA status. Eur J Clin Invest. 1990 Feb;20(1):56-60. [PubMed: 2108037]

9.

Prummel MF, Wiersinga WM. Thyroid peroxidase autoantibodies in euthyroid subjects. Best Pract Res Clin Endocrinol Metab. 2005 Mar;19(1):1-15. [PubMed: 15826919]

10.

Lee SY, Pearce EN. Assessment and treatment of thyroid disorders in pregnancy and the postpartum period. Nat Rev Endocrinol. 2022 Mar;18(3):158-171. [PMC free article: PMC9020832] [PubMed: 34983968]

11.

Stagnaro-Green A. Postpartum thyroiditis. Best Pract Res Clin Endocrinol Metab. 2004 Jun;18(2):303-16. [PubMed: 15157842]

12.

Nicholson WK, Robinson KA, Smallridge RC, Ladenson PW, Powe NR. Prevalence of postpartum thyroid dysfunction: a quantitative review. Thyroid. 2006 Jun;16(6):573-82. [PubMed: 16839259]

13.

Petranović Ovčariček P, Görges R, Giovanella L. Autoimmune Thyroid Diseases. Semin Nucl Med. 2024 Mar;54(2):219-236. [PubMed: 38044176]

14.

Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017 Mar;27(3):315-389. [PubMed: 28056690]

15.

Nikolai TF, Turney SL, Roberts RC. Postpartum lymphocytic thyroiditis. Prevalence, clinical course, and long-term follow-up. Arch Intern Med. 1987 Feb;147(2):221-4. [PubMed: 3492979]

16.

Lazarus JH, Hall R, Othman S, Parkes AB, Richards CJ, McCulloch B, Harris B. The clinical spectrum of postpartum thyroid disease. QJM. 1996 Jun;89(6):429-35. [PubMed: 8758046]

17.

Gerstein HC. How common is postpartum thyroiditis? A methodologic overview of the literature. Arch Intern Med. 1990 Jul;150(7):1397-400. [PubMed: 2196025]

18.

Peng Y, Zhuang K, Huang Y. Incidence and factors influencing delayed onset of lactation: a systematic review and meta-analysis. Int Breastfeed J. 2024 Aug 22;19(1):59. [PMC free article: PMC11342634] [PubMed: 39175092]

19.

Muller AF, Drexhage HA, Berghout A. Postpartum thyroiditis and autoimmune thyroiditis in women of childbearing age: recent insights and consequences for antenatal and postnatal care. Endocr Rev. 2001 Oct;22(5):605-30. [PubMed: 11588143]

20.

Tsakiridis I, Giouleka S, Kourtis A, Mamopoulos A, Athanasiadis A, Dagklis T. Thyroid Disease in Pregnancy: A Descriptive Review of Guidelines. Obstet Gynecol Surv. 2022 Jan;77(1):45-62. [PubMed: 34994394]

21.

Yang Y, Chen H. Clinical Application of Thyrotropin Receptor Antibodies. Horm Metab Res. 2025 Feb;57(2):79-87. [PubMed: 39653332]

22.

Ashkar C, Sztal-Mazer S, Topliss DJ. How to manage Graves' disease in women of childbearing potential. Clin Endocrinol (Oxf). 2023 May;98(5):643-648. [PubMed: 35192205]

23.

Mattsson S, Leide-Svegborn S, Andersson M. X-RAY AND MOLECULAR IMAGING DURING PREGNANCY AND BREASTFEEDING-WHEN SHOULD WE BE WORRIED? Radiat Prot Dosimetry. 2021 Oct 12;195(3-4):339-348. [PMC free article: PMC8507446] [PubMed: 33855370]

24.

Kyrilli A, Unuane D, Poppe KG. Thyroid autoimmunity and pregnancy in euthyroid women. Best Pract Res Clin Endocrinol Metab. 2023 Mar;37(2):101632. [PubMed: 35256265]

25.

Stagnaro-Green A. Clinical review 152: Postpartum thyroiditis. J Clin Endocrinol Metab. 2002 Sep;87(9):4042-7. [PubMed: 12213841]

Disclosure: Karen Carlson declares no relevant financial relationships with ineligible companies.

Disclosure: Beverly Mikes declares no relevant financial relationships with ineligible companies.